If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

Share Price is delayed by 15 minutes
Get Live Data
1.97    0.57 (40.71%)
Bid:
1.70
Ask:
1.98
Spread: 0.28 (16.471%)
Market Cap: £6.91m
PRM Live PriceLast checked at - London Stock Exchange

Intraday Proteome Share Chart

Director Dealing

31 Jul 2008 16:13

For Immediate Release 31 July 2008

PROTEOME SCIENCES plc

("Proteome Sciences" or the "Company")

PRESS RELEASE

DIRECTORS' SHAREHOLDINGS

Proteome Sciences announces that on 31 July 2008 it granted a conditional award of 1,882,500 Ordinary Shares of 1p each in the Company ("Ordinary Shares") to C.D.J. Pearce, Chief Executive and of 1,170,000 Ordinary Shares of 1p each to J.L. Malthouse, Finance Director, under its Long-Term Incentive Plan ("LTIP") based on a closing mid-market price on 30 July 2008 of 20p per Ordinary Share.

In accordance with the rules of the LTIP, the Ordinary Shares awarded will vest 3 years after the date of grant subject to the Company achieving a target total shareholder return (TSR) over a three-year performance period relative to the AIM Healthcare Index at the start of that period. TSR is the aggregate of share price growth and the value of dividend payments during the performance period. No shares will be released unless the Company's TSR performance exceeds that of the index, in which case 30% of the award will vest with full vesting only if the Company's TSR performance exceeds that of the Index by 10%, with a pro-rata award between 30% and 100% for each percentage point of out-performance up to 10%.

The Remuneration Committee of the Board of Directors believes that today's award under the LTIP aligns the interests of shareholders with those of the executive by making the award dependent on the success of management in delivering superior returns to shareholders.

C.D.J. Pearce currently holds 6,538,075 shares in the Company, and has a previous conditional award under the LTIP of up to 504,523 shares.

J.L. Malthouse currently holds 625,000 shares in the Company, and has a previous conditional award under the LTIP of up to 470,352 shares.

Ends

Proteome Sciences plc

Christopher Pearce James Malthouse

Chief Executive Officer Finance Director

christopher.pearce@proteomics.com james.malthouse@proteomics.com

Tel: +44 (0)1932 865065

Nominated Adviser

Landsbanki Securities (UK) Limited

Shaun Dobson / Claes SpĴng Tel: +44 (0)20 7426 9000

vendor
Date   Source Headline
4th Apr 20174:35 pmRNSPrice Monitoring Extension
4th Apr 20177:00 amRNSOption Awards
3rd Apr 20177:00 amRNSAppointment of Richard Dennis as CCO
31st Mar 20174:45 pmRNSBlock Admission Return
28th Mar 20177:00 amRNSPreliminary Results
9th Feb 20177:00 amRNSTrading Update & Notice of Results
4th Jan 20174:36 pmRNSHoldings in Company / PDMR Shareholding
3rd Jan 20171:34 pmRNSHoldings in Company / PDMR Shareholding
30th Dec 201611:42 amRNSHolding(s) in Company
19th Dec 20167:00 amRNSLaunch of new website
16th Dec 20169:28 amRNSHolding(s) in Company
29th Nov 201610:43 amRNSResult of GM and Completion of Placing
18th Nov 20169:46 amRNSHolding(s) in Company
8th Nov 201610:12 amRNSHolding(s) in Company
4th Nov 20163:52 pmRNSDirector/PDMR Shareholding & Total Voting Rights
2nd Nov 20164:35 pmRNSPrice Monitoring Extension
31st Oct 20167:00 amRNSPlacing and Subscription to raise £3.3 million
20th Oct 20164:40 pmRNSSecond Price Monitoring Extn
20th Oct 20164:35 pmRNSPrice Monitoring Extension
4th Oct 20164:35 pmRNSPrice Monitoring Extension
3rd Oct 20167:00 amRNSBlock Admission return
29th Sep 20167:00 amRNSHolding(s) in Company
22nd Sep 20167:00 amRNSPublication: Journal of Alzheimer's disease
15th Sep 20167:00 amRNSHalf-year Report
28th Jul 20167:00 amRNSTrading Update and Notice of Results
24th Jun 201612:30 pmRNSAGM Statement and Result of AGM
1st Jun 20167:00 amRNSAppointment of CEO
31st May 20163:20 pmRNSPublication of Annual Report
18th May 20167:01 amRNSCEO Appointment
18th May 20167:00 amRNSPreliminary Results
5th Apr 20167:00 amRNSDeep Protein Profiling Key re. Cancer Treatment
1st Apr 20168:04 amRNSBlock Admission return
29th Feb 20167:00 amRNSTrading Update
5th Jan 20169:43 amRNSDirector Dealing
14th Dec 20154:02 pmRNSDirector Dealing
14th Dec 20159:36 amRNSHolding(s) in Company
5th Nov 20157:00 amRNSClinical Trial Results for CK1d
1st Oct 20157:00 amRNSBlock Admission return
30th Sep 20157:00 amRNSUnaudited Interim Results
4th Sep 20157:00 amRNSChange of Adviser
17th Jul 201512:01 pmRNSAGM Statement
13th Jul 20152:48 pmRNSHolding(s) in Company
3rd Jul 20155:03 pmRNSHolding(s) in Company
23rd Jun 20157:05 amRNSPublication of Annual Report
23rd Jun 20157:00 amRNSPlacing to raise £2.5 million
29th May 20157:00 amRNSPreliminary results
30th Mar 20154:21 pmRNSBlocklisting Interim Review
9th Mar 20157:00 amRNSTrading Statement
1st Dec 20143:15 pmRNSDirectorate Change
28th Nov 20147:00 amRNSSysQuant - Update/Contract Awards

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.